Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-cd9895bd7-gxg78 Total loading time: 0 Render date: 2024-12-26T17:51:38.007Z Has data issue: false hasContentIssue false

2 - Antitrust and Intellectual Property: Developments in Pharmaceuticals

from Part I - Economics of Antitrust-IP

Published online by Cambridge University Press:  04 May 2017

By
Sumanth Addanki
Edited by
Roger D. Blair  and
D. Daniel Sokol
Roger D. Blair
Affiliation:
University of Florida
D. Daniel Sokol
Affiliation:
University of Florida
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
The Cambridge Handbook of Antitrust, Intellectual Property, and High Tech , pp. 21 - 42
Publisher: Cambridge University Press
Print publication year: 2017

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Addanki, Sumanth and Butler, Henry N.. 2014. Activating Actavis: Economic Issues in Applying the Rule of Reason to Reverse Payment Settlements. Minnesota Journal of Law, Science & Technology, 15(1), 77–94.Google Scholar
Addanki, Sumanth and Daskin, Alan J.. 2008. Patent Settlement Agreements. ABA Section of Antitrust Law, 3, 2127–53.Google Scholar
Cotter, Thomas F. 2004. Antitrust Implications of Patent Settlements Involving Reverse Payments: Defending a Rebuttable Presumption of Illegality in Light of Some Recent Scholarship. Antitrust Law Journal, 71(3), 1069–97.Google Scholar
Cramer, Eric L. and Berger, Daniel. 2004. The Superiority of Direct Proof of Monopoly Power and Anticompetitive Effects in Antitrust Cases Involving Delayed Entry of Generic Drugs. University of San Francisco Law Review, 39, 81–140.Google Scholar
Drake, Keith M., Starr, Martha A., and McGuire, Thomas. 2014. Do “Reverse Payment” Settlements of Brand-Generic Patent Disputes in the Pharmaceutical Industry Constitute an Anticompetitive Pay for Delay? NBER Working Paper No. 20292. July.CrossRefGoogle Scholar
Edlin, Aaron, Hemphill, Scott, Hovenkamp, Herbert, and Shapiro, Carl. 2013. Activating Actavis. Antitrust Magazine, 28(1), 16–23.Google Scholar
Elhauge, Einer and Krueger, Alex. 2012. Solving the Patent Settlement Puzzle. Texas Law Review, 91, 283–330.Google Scholar
Federal Trade Commission. 2006. Prepared Statement of the Federal Trade Commission Before the Special Committee on Aging of the United States Senate on Barriers to Generic Entry. Available at www.ftc.gov/sites/default/files/documents/public_statements/prepared-statement-federal-trade-commission-generic-drug-entry/p052103barrierstogenericentrytestimonysenate07202006.pdf.Google Scholar
Federal Trade Commission. 2015. Brief for Amicus Curiae Federal Trade Commission Supporting Plaintiff-Appellant in Mylan Pharmaceuticals, Inc. v. Warner Chilcott plc, et al.. Available at www.ftc.gov/system/files/documents/amicus_briefs/mylan-pharmaceuticals-inc.v.warner-chilcott-plc-et-al./151001mylanamicusbrief.pdf.Google Scholar
Golden Gate Pharmacy Services, Inc. v. Pfizer, Inc., No. 10–15978 (9th Cir. May 19, 2011).Google Scholar
Harris, Barry C., Murphy, Kevin M., Willig, Robert D., and Wright, Matthew B.. 2014. Activating Actavis: A More Complete Story. Antitrust Magazine, 28(2), 83–9.Google Scholar
Heading for the Emergency Room. 2009. The Economist, June 25. Available at www.economist.com/node/13899647.Google Scholar
Hirsh, Merrill and Dorfman, Dan Zoloth. 2005. I Didn’t Say Orphan Often: The Benefits of a Bright-Line Rule Barring Brand to Generic Payments in Hatch-Waxman Patent Settlements. Antitrust Health Care Chronicle, 19(2).Google Scholar
Lamberti, Mary J. and Getz, Kenneth. 2015. Profiles of New Approaches to Improving the Efficiency and Performance of Pharmaceutical Drug Development. Tufts Center for the Study of Drug Development White Paper. Available at http://csdd.tufts.edu/files/uploads/CSSD_PhRMAWhitePaperNEWEST.pdf.Google Scholar
Langenfeld, James. 2013. Evaluating the Size of “Reverse Payments” in Light of the Supreme Court’s Decision in FTC v. Actavis. CPI Antitrust Chronicle. Available at www.competitionpolicyinternational.com/evaluating-the-size-of-reverse-payments-in-light-of-the-supreme-court-s-decision-in-ftc-v-actavis-2/.Google Scholar
Leffler, Keith B. and Leffler, Cristofer I.. 2002. Want to Pay a Competitor to Exit the Market? Settle a Patent Infringement Case; An Argument for Per Se Condemnation of Payments by the Patent Holder. ABA Section of Antitrust Law Economics Committee Newsletter, Spring, 26–35.Google Scholar
Meijer, Inc. v. Barr Pharmaceuticals, Inc., 572 F. Supp. 2d 38 (D.C. 2008).Google Scholar
Mylan Pharmaceuticals, Inc. v. Warner Chilcott plc, et al. Civ. No. 12–3824 (E.D. Pa. Apr. 16, 2015).Google Scholar
National Science Foundation. 2015. Business Research and Development and Innovation: 2012. Available at www.nsf.gov/statistics/2016/nsf16301/.Google Scholar
Orszag, Jonathan. 2013. Statement of Jon Orszag Before the Committee on Senate Judiciary Subcommittee on Antitrust, Competition Policy and Consumer Rights. Available at www.judiciary.senate.gov/imo/media/doc/CHRG-113shrg87818.pdf.Google Scholar
Padilla, Jorge and Meunier, Valerie. 2015. Should Reverse Payment Patent Settlements Be Prohibited Per Se? Available at http://ssrn.com/abstract=2604071.CrossRefGoogle Scholar
Robbins, Gary, Robbins, Aldonna, and Goodman, John. 1994. Inefficiency in the U.S. Health Care System: What Can We Do? NCPA Policy Report No. 182. Available at www.ncpa.org/pdfs/st182.pdf.Google Scholar
Schering-Plough Corp. v. FTC, 402 F.3d 1056, 1060 (11th Cir. 2005).Google Scholar
Shapiro, Carl F. 2003. Antitrust Limits to Patent Settlements. RAND Journal of Economics, 34(1), 391–411.CrossRefGoogle Scholar
UK National Health Service. 2014. Medicines information – Licensing. Available at www.nhs.uk/conditions/Medicinesinfo/pages/safetyissues.aspx.Google Scholar
US Food and Drug Administration. 2014. “Off-Label” and Investigational Use of Marketed Drugs, Biologics, and Medical Devices – Information Sheet. Available at www.fda.gov/RegulatoryInformation/Guidances/ucm126486.htm.Google Scholar
US Food and Drug Administration. 2015. Applications for FDA Approval to Market a New Drug. Available at www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=314.Google Scholar
Vivian, Jesse C. 2008. Generic-Substitution Laws. U.S. Pharmacist. Available at www.uspharmacist.com/content/s/44/c/9787/.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×